Roflumilast

Category: pharmacological

Aliases: Daliresp

Pharmacological Mechanism

Selective PDE4 inhibitor — anti-inflammatory effect on bronchial inflammation. Oral approval for severe COPD with chronic bronchitis. Weight loss + GI / psychiatric side effects limit use.

Half-Life (t½)

PO: 17h

Dosing Guidelines

• PO: Typical 0.5mg (Range: 0.25 - 0.5 mg)

Target Organ Systems

• respiratory
• immune-hematologic